Gilead seeks full control of BCMA CAR-T franchise via USD 7.8b acquisition of Arcellx

Gilead Sciences has agreed to acquire US-based clinical-stage cell therapy developer Arcellx for an implied equity value of USD 7.8 billion in cash and contingent payments. The transaction is intended to consolidate long-term strategic control over anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy, within Gilead’s Kite oncology division as the company advances deeper into autologous and in vivo cell therapy platforms.

Deal terms & financials

Under the terms of the agreement, Gilead will pay USD 115 per Arcellx share in cash at closing alongside a contingent value right (CVR) of USD 5 per share tied to cumulative global net sales of anito-cel reaching USD 6.0 billion by the end of 2029. The offer represents a 68% premium to Arcellx’s 30-day volume-weighted average share price as of February 20, 2026. The deal is expected to close in Q2 2026, subject to regulatory approvals and shareholder tender conditions.

Anito-cel is currently under regulatory review following acceptance of a biologics license application (BLA) by the US FDA for use as a fourth-line treatment in adults with relapsed or refractory multiple myeloma. The filing is supported by Phase I data (NCT04155749) and results from the pivotal Phase II iMMagine-1 trial (NCT05396885), positioning the asset at a pre-commercial regulatory stage with a Prescription Drug User Fee Act action date of December 23, 2026.

D-Domain CAR architecture and BCMA targeting

At the core of the acquisition is Arcellx’s proprietary D-Domain CAR platform, which replaces conventional single-chain variable fragment (scFv) binding motifs with compact, synthetic protein domains engineered for improved target specificity and binding affinity. In the case of anito-cel, the construct is designed to recognize B-cell maturation antigen (BCMA), a transmembrane receptor expressed on malignant plasma cells that regulates survival signaling through APRIL- and BAFF-mediated pathways.

By leveraging D-domain binding elements, the CAR construct is intended to reduce tonic signaling and mitigate antigen-independent T-cell activation, a known contributor to exhaustion phenotypes and cytokine release syndrome in earlier-generation BCMA CAR-T designs. This structural approach may also facilitate adaptation for in vivo CAR-T delivery systems, where endogenous T cells are transduced directly within the patient using viral or non-viral vectors, bypassing the logistical and manufacturing bottlenecks associated with autologous ex vivo expansion. These constraints, including vein-to-vein manufacturing timelines and cold-chain transport requirements, represent a limiting factor in current commercial BCMA-targeted therapies.

Industry context

Gilead’s acquisition aligns with ongoing consolidation within the BCMA-directed cellular immunotherapy space, which has seen increasing investment as CAR-T platforms migrate into earlier lines of therapy for multiple myeloma.

Industry benchmarks include:

• Bristol Myers Squibb’s idecabtagene vicleucel (Abecma), a BCMA-directed CAR-T therapy approved for relapsed or refractory multiple myeloma – fully controlled by BMS after the purchase of 2seventy bio completed in March 2025.
• Johnson & Johnson and Legend Biotech’s ciltacabtagene autoleucel (Carvykti), viewed as the best-in-class BCMA-targeted CAR-T after demonstrating extended progression-free survival in earlier-line multiple myeloma settings.
• Autolus Therapeutics’ AUTO8 program, an autologous BCMA CAR-T candidate incorporating next-generation binding domains to reduce immunogenicity.
• Other acquisitions in the BCMA CAR-T space include AstraZeneca’s USD 1.2 billion purchase of Gracell Biotechnologies, and Roche’s purchase of Poseida Therapeutics for over USD 1 billion, both deals announced in 2024.